Wechselwirkungen · Harvoni
Harvoni 33.75 mg/150 mg coated granules in sachet Harvoni 45 mg/200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 47
HOS-132310 · Präparat HOS-097208
Medicinal product by Effects on medicinal Recommendation concerning co-administration therapeutic areas product levels. with Harvoni Mean ratio (90% confidence interval) for AUC, Cmax, Cmina, b ACID REDUCING AGENTS Ledipasvir solubility decreases as pH increases. Medicinal products that increase gastric pH are expected to decrease concentration of ledipasvir. Antacids e.g. Aluminium or Interaction not studied. It is recommended to separate antacid and Harvoni magnesium hydroxide; Expected: administration by 4 hours. calcium carbonate ↓ Ledipasvir ↔ Sofosbuvir ↔ GS-331007
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): magnesium hydroxide (HOS-088789) calcium carbonate (HOS-088370)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 744d286fc3d13845afff60fc806f8f62d055b410580cc178123ada5d5d9eda6c · Zeichen 2832–3842 im Abschnitt